At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE
In Brief
A Phase 3 clinical trial evaluating Nivolumab, Sitravatinib, and 1 other intervention for Metastatic Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 577 participants across 261 sites in 12 countries.
Detailed Summary
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Study Details
Timeline
Interventions
Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.